Ravuconazole

Drug Profile

Ravuconazole

Alternative Names: BMS 207147; ER 30346

Latest Information Update: 06 Aug 2007

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Class Antifungals; Azoles; Small molecules
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Aspergillosis; Candidiasis; Histoplasmosis; Mycoses; Onychomycosis

Most Recent Events

  • 06 Aug 2007 Discontinued - Phase-I/II for Onychomycosis in Canada (PO)
  • 06 Aug 2007 Discontinued - Phase-II for Aspergillosis in USA (unspecified route)
  • 06 Aug 2007 Discontinued - Phase-II for Candidiasis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top